Novo Nordisk A/S (NYSE:NVO) Valuation According To Analysts

Henrietta Strickland
October 20, 2017

Novo Nordisk A S (ADR) (NYSE:NVO) has declined 23.93% since October 19, 2016 and is downtrending.

GlaxoSmithKline plc (GSK) analysts on average have given a price target of $50.2 on GSK stock.

Novo Nordisk A/S (NVO) ended its previous trading session at $49.31 with the Loss of -0.02%.

Blair William & Company decreased Stericycle Inc (NASDAQ:SRCL) stake by 17,723 shares to 332,671 valued at $25.39 million in 2017Q2. The segment is driven by strong performance of drugs like Victoza, Tresiba, Saxenda and Xultophy among others. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has almost 5,000 employees in the United States. The Business's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.

Among 2 analysts covering Lands' End (NASDAQ:LE), 0 have Buy rating, 0 Sell and 2 Hold.

Novo Nordisk is hoping to begin marketing semaglutide starting next year, with analysts in published reports estimating the treatment will generate annual sales of $2 billion. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) has "Neutral" rating given on Friday, September 9 by JP Morgan. If the $53.14 price target is reached, the company will be worth $4.98B more.

Analysts await Novo Nordisk A S (ADR) (NYSE:NVO) to report earnings on October, 27. With short interest at 3,617,079 and short average daily volume at 1,644,086, days to cover is 2.0 and the percentage of shorted shares was 0.00% on September 29.

The stock's 50 day moving average is 48.56 and its 200 day moving average is 43.36. Novo Nordisk's glucagon-like peptide-1 receptor (GLP-1) cut the hemoglobin A1C (HbA1C) of patients by 1.5% compared with 1.1% by dulaglutide at the low dose, and 1.8% compared with 1.4% at the high dose. The stock has a market capitalization of $125.32 billion, a price-to-earnings ratio of 20.3248 and a beta of 0.61. The stock has "Hold" rating by Zacks on Friday, August 28. If you are reading this report on another website, it was copied illegally and republished in violation of USA & worldwide copyright & trademark law. BNP Paribas upgraded the shares of NVO in report on Tuesday, September 13 to "Outperform" rating. It increased, as 15 investors sold Community Bank System, Inc. shares while 30 reduced holdings. Proficio Capital Partners LLC raised its position in Novo Nordisk A/S by 155.6% in the first quarter.

For the ongoing Fiscal Quarter, 1 analysts have an average earnings forecast of $0.53 per share. Donaldson Capital Management Llc acquired 11,489 shares as Novo (NVO)'s stock rose 15.20%. The Loring Wolcott & Coolidge Fiduciary Advisors Llp holds 1.12M shares with $47.53 million value, down from 1.31 million last quarter.

(NYSE:NVO) shares saw light trading volume with 109K shares changing hands in the last trading session.

As of the end of the quarter Fisher Asset Management, LLC had bought a total of 433,727 shares growing its holdings by 3.7%. Hedge funds and other institutional investors own 6.01% of the company's stock.

Novo Nordisk is on track to win FDA approval later this year to market the first once-weekly type 2 diabetes treatment following an advisory committee's unanimous recommendation yesterday in favor of the company's semaglutide. The Firm markets its products in the United States, Europe, Latin America, Canada, and Asia. The Firm operates through two business divisions: diabetes and obesity care, and biopharmaceuticals.

Other reports by Click Lancashire

Discuss This Article